Search Deep Brain Reorienting and the results sit alongside brain stimulation devices, neurofeedback clinics and implant procedures. It is none of those, and the name is doing the damage.
DBR entered the published literature in 2020, and one randomized trial has tested it since. That second fact is the one most pages about DBR leave out. The model DBR rests on and the evidence that DBR works are two different claims, and almost everything written about this therapy merges them.
Where Deep Brain Reorienting came from
DBR was developed by psychiatrist Frank Corrigan, who described it in the peer-reviewed literature with Jessica Christie-Sands in a 2020 paper in Medical Hypotheses. The clinical problem behind it is a familiar one in trauma work. Some people improve steadily in therapy that works through the story and the meaning of what happened. Some do not, and for that second group the standard approaches can feel like covering the same ground with better vocabulary.
Corrigan's proposal was to go earlier in the chain. If something in the body's first, pre-conscious response to threat is still running, then working on the memory and the emotion is working downstream of the problem. The name describes the intention: reorienting a response that starts deep in the brain, below the level where thinking happens.
The sequence the therapy is built around
The model proposes an ordered sequence inside a traumatic event, and the order is the whole point. First comes orienting tension. Something happens, and before you have any idea what it is, the muscles that move your eyes, head and neck brace to turn toward it. Second comes shock, a jolt of arousal. Only third do the emotions arrive: fear, rage, shame, grief. On this account, the emotion everyone remembers is the third thing that happened, not the first. That is why the ordering matters: DBR aims at the first stage, where most trauma therapies engage with the third.
That is why a practitioner working this way attends to sensation and tension around the eyes, face, head, neck and shoulders. Those are where the orienting response is proposed to live, and the model treats what is left of that first movement as the material the therapy works with.
Two things about all of that need saying plainly. It is a proposed mechanism. The structures named are real and their general functions are well established, but the claim that a specific trauma sequence is held in the brainstem and can be reached through attention to neck and eye tension is a theoretical model, and it is the model that guided how the therapy was designed. It has not been demonstrated. You will find it written as settled fact on a great many pages, and that confident phrasing is the most misleading thing in the public material about DBR. Redefine's own description of DBR is written that way too: it says the therapy works by accessing the physiological sequence of trauma stored in the brainstem. That is how the modality describes itself, and this article treats it as the model's claim rather than as a finding, because that is what the research so far supports.
Do you have to describe what happened again?
The narrative is not the working material in DBR. The therapy is oriented toward the physiological response rather than toward a retold account of the event, which is a real difference from approaches that ask you to go through what happened in sequence and in detail. That is the part of the question most people are actually asking.
What the model does require is that the event is identified. Something has to be oriented toward, so the work stays tied to a specific root experience rather than to a diagnosis or a general sense of being unwell. How much you say about it, and how that is handled, is a conversation to have with a clinician before starting. No web page can answer it for your situation.
What the research has actually tested
One randomized controlled trial of DBR has been published. Kearney and colleagues, with Corrigan among the authors, ran it in the European Journal of Psychotraumatology in 2023: 54 adults with PTSD, randomly assigned 29 to DBR and 25 to a waitlist, with the DBR group receiving eight weekly sessions of 90 minutes each by videoconference. The waitlist group received nothing during that period. Symptoms were measured with the Clinician Administered PTSD Scale, the structured interview used as the standard in this field.
It is worth knowing in that much detail, because the version of this trial circulating online is consistently more flattering than the study itself.
The results were substantial. Of those who received DBR, 48.3% no longer met the criteria for PTSD at the end of treatment, and 52.0% no longer met them three months later. Total symptom scores fell 36.6% against 8.0% in the waitlist group, with large effect sizes. For a first trial of a new therapy these are results that justify further study, and they put DBR on the list of things worth asking about when you are weighing PTSD treatment options.
What that trial cannot tell you
The 2023 trial has three limitations, and the study's own authors state all three: it could not confirm the brainstem mechanism, it compared DBR against a waitlist rather than against an established treatment, and it excluded several groups of people who commonly have PTSD. Together those set a firm ceiling on what the 48.3% figure can be used to claim. Each one is worth taking separately.
The trial tested the therapy, not the theory. In their words, the analysis "was limited to behavioural data and thus we cannot confirm involvement of subcortical neural mechanisms responsible for DBR treatment efficacy." The brain imaging arm that would have examined the brainstem mechanism was left underpowered, by COVID-19 restrictions and by a scanner going out of service. So the result supports the claim that the therapy helped these participants. It says nothing about whether the brainstem model explaining why is correct.
The only comparison was against nothing. The authors are equally direct here: "we compared the efficacy of DBR only to a waitlist condition, and future studies are required to evaluate the relative efficacy of DBR in comparison to, or in adjacency with, current gold-standard treatments." A waitlist controls for time passing. It cannot tell you whether DBR performs better, worse or the same as an established treatment, because no established treatment was in the study. Any claim that DBR works deeper, faster or better than other trauma therapies has no trial behind it.
The sample was narrow. It was small, predominantly White and female, and it excluded people with pronounced identity instability, with active suicidal intent or a plan, and with co-occurring bipolar disorder, psychotic disorders or active substance use disorders. That last exclusion matters for a lot of readers. If you are dealing with trauma alongside a substance use disorder, people in your situation were not in this trial.
By comparison, the 2023 VA and Department of Defense clinical practice guideline for PTSD recommends cognitive processing therapy, prolonged exposure and EMDR as first-line trauma-focused psychotherapies. DBR is not among them, and one waitlist-controlled trial is not the kind of evidence that puts a therapy on that list.
None of this means DBR does not work. It means the evidence is early, and early is a different thing from weak, and a different thing again from proven.
Where DBR sits among the other trauma therapies
DBR belongs to the same family as EMDR, Brainspotting and Somatic Experiencing: approaches that work with the body's response rather than primarily through discussion. It is not a version of any of them. The clearest contrast is with EMDR, which uses bilateral stimulation while a person engages with a memory. DBR does not do that, and it is aiming at an earlier point in the response than the memory itself.
Redefine Wellness & Treatment offers DBR alongside those three and Internal Family Systems, and describes it as working from the bottom up through body-based responses rather than managing symptoms from the top down. In Redefine's own description, DBR is used with PTSD and complex trauma, particularly where early attachment disruption has led to dissociative symptoms, and it focuses less on the clinical diagnosis than on identifying the root traumatic event. Complex trauma and PTSD are not the same presentation, and the difference between complex PTSD and PTSD matters more here than it does for most therapies, because the trial evidence above covers only the second of the two.
Whether DBR fits your situation is a clinical question rather than a reading one, and it turns on things a web page does not know: what happened, what you have already tried, and how you responded to it. Redefine offers Deep Brain Reorienting as part of that conversation rather than as its conclusion. If it turns out not to suit you, the other clinical therapies available include the trauma approaches named above and several that work differently again.
No, and the two have nothing in common beyond three words. Deep brain stimulation is a neurosurgical procedure that implants electrodes in the brain, used mainly for Parkinson's disease and for some treatment-resistant psychiatric conditions. Deep Brain Reorienting is a psychotherapy conducted in conversation, with no device and no procedure at any point.
Broadly, yes. It works with physical sensation rather than through discussion of the narrative, which puts it in the somatic family alongside Somatic Experiencing. That label covers a lot of ground, though, and what separates DBR from the rest of somatic therapy is how narrow its target is: the orienting response, not body sensation in general.
Every session in the 2023 trial was delivered by videoconference. That is an unusual detail for a therapy whose working material is physical tension in the face and neck, and it cuts both ways when reading the results, so it is worth holding on to.
Not currently. The 2023 VA and Department of Defense clinical practice guideline names cognitive processing therapy, prolonged exposure and EMDR as the trauma-focused psychotherapies for PTSD. With one published randomized trial, DBR does not have the volume of evidence that guideline inclusion requires. That is a statement about how much research exists, not a verdict on the therapy.
